MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Aprovel 300mg tablets (Sanofi).

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

Tablets are hygroscopic. Contains desiccant therefore unsuitable.

Provenance

This compatibility recommendation is derived from Arava 10mg tablets (Sanofi) and Leflunomide 10mg tablets (Sandoz Ltd).

Stability Notes

Tablets are hygroscopic. Contains desiccant therefore unsuitable.

Provenance

This compatibility recommendation is derived from Arava 10mg tablets (Sanofi) and Leflunomide 10mg tablets (Sandoz Ltd).

Stability Notes

Tablets are hygroscopic. Contains desiccant therefore unsuitable.

Provenance

This compatibility recommendation is derived from Arava 20mg tablets (Sanofi) and Leflunomide 20mg tablets (Sandoz Ltd).

Stability Notes

Tablets are hygroscopic. Contains desiccant therefore unsuitable.

Provenance

This compatibility recommendation is derived from Arava 20mg tablets (Sanofi) and Leflunomide 20mg tablets (Sandoz Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arcoxia 120mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arcoxia 120mg tablets (Organon Pharma (UK) Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.